Small and Mid-Size Farms
ID: 8.12Type: Phase II
Overview

Topic

Small and Mid-Size Farms

Agency

Department of AgricultureNational Institute of Food and Agriculture

Program

Type: BOTHPhase: Phase IIYear: 2024

Topic Link

https://www.sbir.gov/node/2482413

Additional Information

https://www.nifa.usda.gov/grants/funding-opportunities/small-business-innovation-research-small-business-technology
Timeline
  1. 1
    Release Nov 14, 2023 12:00 AM
  2. 2
    Open Nov 14, 2023 12:00 AM
  3. 3
    Next Submission Due Mar 26, 2024 12:00 AM
  4. 4
    Close Mar 26, 2024 12:00 AM
Description

The Department of Agriculture's National Institute of Food and Agriculture is seeking proposals for the Small Business Innovation Research and Small Business Technology Transfer Programs Phase II. The specific topic of the solicitation is "Small and Mid-Size Farms." The goal of this topic is to promote and improve the sustainability and profitability of small and mid-size farms and ranches. The research aims to benefit farms with annual sales of agricultural products less than $350,000 for small farms and between $350,000 and $999,999 for mid-size farms. The solicitation is closed, and the project duration and funding specifics can be found on the USDA-NIFA website.

Files
No associated files provided.
Similar Opportunities
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). This solicitation encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. The program supports milestone-driven, hypothesis-driven clinical trials related to the research mission of the NIAID that address high-priority research areas. The solicitation encourages high-risk clinical studies, which involve non-routine interventions, administration of unlicensed products, or administration of licensed products for unapproved indications. Mechanistic studies are also encouraged. The funding supports the conduct, completion, and analysis of a single clinical trial, including activities such as training of study personnel, enrollment and recruitment of study subjects, data collection and management, laboratory work, study management and oversight, safety monitoring, and regulatory activities. The project duration is not specified, but the solicitation is open until January 14, 2027. The funding specifics can be found on the grants.nih.gov website.
Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of novel tools and devices for animal research facilities and to support the care of animal models. The Office of Research Infrastructure Programs (ORIP) is encouraging applications from small business concerns (SBCs) for Small Business Innovation Research (SBIR) projects in this area. The goal of this solicitation is to improve animal welfare, ease the management of individual animals and animal colonies, and enhance the monitoring and control of environmental conditions that affect outcomes and reproducibility in animal model research. The variation of extrinsic factors between different animal facilities has been cited as a source of irreproducibility in animal research, and this solicitation aims to address this issue. The solicitation specifically calls for the development and implementation of novel tools and devices to monitor environmental conditions, identify pathogens and contaminants, and enable noninvasive or minimally invasive monitoring of animal behavior and bodily functions. The devices should be discreet, robust, easy to apply, and mobile. Additionally, the solicitation seeks new software that can combine data from different monitoring devices and be compatible with different data formats. The solicitation emphasizes the importance of innovation and encourages the adaptation of technologies from other fields to improve animal research. It applies to a broad range of animal models, including invertebrate and vertebrate animals, and excludes disease-specific devices, reagents, and experimental protocols. Examples of specific tools and devices that can be developed include portable software for managing and evaluating animal colonies, noninvasive tracking and monitoring technology, automated feeding systems, devices for drug delivery and measurement, improved systems for data collection and analysis, better phenotyping devices, improved holding and transfer devices, and enhanced air and water filters for animal facilities. The solicitation is open for applications until September 6, 2024, and applicants are advised to discuss their projects with the Scientific/Research contacts before submitting an application. More information can be found on the grants.gov website.
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). This solicitation encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. The program supports milestone-driven, hypothesis-driven clinical trials related to the research mission of the NIAID that address high-priority research areas. The solicitation encourages high-risk clinical studies, which involve non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged. The funding supports the conduct, completion, and analysis of a single clinical trial, including activities such as training of study personnel, enrollment and recruitment of study subjects, data collection and management, laboratory work, safety monitoring, and regulatory activities. The project duration is not specified, but the application due dates are provided. More information can be found on the grants.gov website.
Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the Small Business Transition Grant for Early Career Scientists. This grant aims to support early-career academic scientists interested in transitioning to entrepreneurship while also facilitating the transfer of technology from academic laboratories into small businesses. The eligibility for this grant is limited to applicants with 10 years or less of post-graduate experience. The grant allows for Phase I only Small Business Technology Transfer (STTR) applications, as well as Fast-Track applications that transition from Phase I STTR to Phase II Small Business Innovation Research (SBIR). The Phase I STTR allows for more work to be completed at the university and provides flexibility in terms of principal investigator (PI) employment. Upon successful completion of Phase I, fast-track applications transition to Phase II as an SBIR award, requiring the PI to move their employment to the small business and limiting university involvement. Mentoring is a crucial component of this grant, and a mentoring plan is required in the application. The ideal candidate for this grant is a postdoctoral researcher who has participated in technology discovery during their academic work and is ready to move to a small business with the support of an experienced team. Proposed projects must pertain to the mission space of one of the participating Institutes, including the National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, National Human Genome Research Institute, and National Institute of Mental Health. Each Institute has specific areas of research interest, and applicants are encouraged to contact the Scientific/Research Contacts from the respective Institutes to discuss program relevance. The grant has key requirements, including the need for strong mentors, eligibility limited to early-career scientists, and alignment with the scientific/technical scope of the participating Institutes. Additionally, there are specific requirements for each Institute, such as completion of entrepreneurship training programs. The transition from Phase I to Phase II is contingent upon meeting certain criteria, including a Phase I final progress report, an updated commercialization plan, updated IP agreements, letters of support from mentors, completion of entrepreneurship programs, and verification of SBIR eligibility. The grant provides an opportunity for early-career scientists to transition to entrepreneurship and supports the advancement of technologies from academic research laboratories to small businesses.
NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) topic. This solicitation aims to support small business concerns (SBCs) in conducting exploratory clinical trials that contribute to the justification for future trials to establish definitive efficacy. The trials can include Phase 1 and 2 studies of drugs and biologics, feasibility and preliminary efficacy studies of devices, as well as early studies of surgical, behavioral, or rehabilitation therapies. The trials can be single-site or multi-site with up to three clinical sites. The applications must generate data that inform further clinical development of the proposed intervention or diagnostic, and FDA approval is required for FDA-regulated clinical trials. The goal is to advance products/technologies that require federal regulatory approval or bring complex research tools to market. The solicitation is open until September 6, 2026, and more information can be found at the provided links.